2-benzyl-4-methylbenzo[d]thiazole | 1374225-51-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 2-benzyl-4-methylbenzo[d]thiazole
• 英文别名: 2-Benzyl-4-methyl-1,3-benzothiazole
• CAS: 1374225-51-0
• 化学式: C₁₅H₁₃NS
• 分子量: 239.341
• InChiKey: OMFHNMAENBEZFC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (Z)-2-methyl-6-(styrylthio)aniline 在 碘 作用下， 以 1,2-二氯乙烷 为溶剂， 以55%的产率得到2-benzyl-4-methylbenzo[d]thiazole
  参考文献：
  名称：

  Iodine-Mediated Intramolecular Oxidative Cyclization of 2-(Styrylthio)anilines: Synthesis of 2-Substituted Benzothiazoles

  摘要：

  本文介绍了一种新型的无金属碘介导的分子内氧化环化方案，该方案可用于制备各种 2-取代的苯并噻唑。

  DOI：

  10.1055/s-0031-1289692

文献信息

• Neurofibrillary labels
  申请人：Wischik Claude Michel

  公开号：US20100285605A1

  公开（公告）日：2010-11-11

  Disclosed are methods for determining the stage of neurofibrillary degeneration associated with a tauopathy in a subject believed to suffer from the disease, which methods comprise the steps of: (i) introducing into the subject a ligand capable of labelling aggregated paired helical filament (PHF) tau protein, (ii) determining the presence and\or amount of ligand bound to extracellular aggregated PHF tau in the medial temporal lobe of the brain of the subject, (iii) correlating the result of the determination made in (ii) with the extent of neurofibrillary degeneration in the subject. The methods can be used for pre-mortem diagnosis and staging of tauopathies such as Alzheimer's Disease. Preferred ligands include sulphonated-benzothiazole-like compounds and diaminophenothiazines. Novel ligands (e.g. sulphonated-benzothiazole-like compounds) are also provided. The method may also include the use of “blocking ligands” to block competing binding sites. In other aspects the invention provides in vitro methods for identifying ligands capable of labeling aggregated PHF tau protein, the methods comprising the steps of: (i) providing a first agent suspected of being capable of labeling aggregated PHF tau protein, (ii) contacting (a) a tau protein or a derivative thereof containing the tau core fragment bound to a solid phase so as to expose a high affinity tau capture site, with (b) a liquid phase tau protein or derivative thereof capable of binding to the solid phase tau protein or derivative, and (c) said selected first agent and (d) a second agent known to be tau-tau binding inhibitor, (iii) selecting first agent which fully or partially relieves the inhibition of binding of the liquid phase tau protein or derivative of (b) to the solid phase tau protein or derivative of (a) by the inhibitor (d). Ligands may also be tested to confirm that they are not themselves inhibitors.
• US8097615B2
  申请人：——

  公开号：US8097615B2

  公开（公告）日：2012-01-17